@Reydiy This is another Omega 3 fatty acid drug development company, with similar focus to $ACST. Presentation overview on Dec 3, could get sympathy play if $ACST has good Phase 3 results in December, without the risk for 80%+ selloff on bad $ACST news. I still have a position in $ACST, but am going to build on $MTNB, and just hold the ACST for now.
  • 12